- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Top 5 Most-Read Colorectal Cancer Articles of 2023
The topics included clinical staging of colorectal cancer, FDA approvals, and a study published in the print version of the American Journal of Managed Care®.
A study published in the American Journal of Managed Care® (AJMC), FDA approvals, information on medication buyouts, and the increase of clinical staging in colorectal cancer (CRC) were among the topics covered in the top 5 most-read articles about CRC on AJMC.com.
These are the top 5 articles for CRC in 2023.
5. Clinical Staging of Colorectal Cancer Increased in Post–COVID-19 Period
When evaluating the timeframes before and after the COVID-19 pandemic, decreases in the number and availability of screenings for cancer during the pandemic led to stage migration in the initial diagnosis of CRC. There was a notable decrease in patients who received a diagnosis of CRC at clinical stage T1 (–8.73%) and clinical stage 0 (–2.80%) when comparing the 22 months before to the 22 months after the pandemic. An increase in clinical stage T4 diagnoses were found in that same timeframe (12.67%).
4. FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC
An article originally published on OncLive® reported that the FDA had granted fam-trastuzumab deruxtecan-nxki (Enhertu) 2 breakthrough therapy designations to treat patients with unresectable or metastatic solid tumors that had progressed after prior treatment in patients with HER2-positive metastatic CRC (mCRC). The DESTINY-CRC01 and DESTINY-CRC02 phase 2 trials were used as the basis of the approval for treatment in CRC specifically. DESTINY-CRC01 demonstrated an objective response rate of 45.3% whereas the DESTINY-CRC02 had a confirmed objective response rate of 37.8%.
3. Takeda Stakes $1.13 Billion on Rights to Fruquintinib for Advanced Refractory Colorectal Cancer
Fruquintinib, an oral inhibitor of vascular endothelial growth factor receptors-1, -2, and -3, were licensed by Takeda in January to develop and commercialize for subtypes of refractory metastatic CRC. Takeda planned to pay Hutchmed $400 million up front and up to $730 million in additional payments that were related to regulatory, development, and commercial sales milestones. The drug had met its primary end point of improving overall survival in a phase 3 multiregional clinical trial of patients with refractory metastatic CRC.
2. A “Sludge Audit” for Health System Colorectal Cancer Screening Services
A study published in the print version of AJMC found that a sludge audit method was able to identify and quantify sludge in the screening processes for CRC performed by a health system. The authors found that there was a 60.4% screening rate, with half of screening orders not completed. Sludge was found in the health system’s communication, time, administrative tasks, technology, paperwork, and low-value care. Effective screening for CRC can be achieved through further sludge audits.
1. FDA Approves Trifluridine/Tipiracil Plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer
The FDA approved trifluridine and tipiracil (Lonsurf) and bevacizumab (Avastin) as a joint treatment for patients with metastatic CRC who had been previously treated. Data from the SUNLIGHT phase 3 trial was used as a basis for the approval, which found that there was a 39% reduction of the risk of death when using bevacizumab with trifluridine/tipiracil compared with using trifluridine/tipiracil alone. The risk of disease progression or death also saw a 56% reduction when using bevacizumab.
Treatment Combinations Based in Immune Checkpoint Inhibitors Provide Survival Benefits in CRC
December 13th 2024Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using combinations based in immune checkpoint inhibitors.
Read More
